相关实验视频
Updated: Jan 13, 2026

05:48
Rapid Generation of Amyloid from Native Proteins In vitro
Published on: December 5, 2013
6.5K
获得和遗传性粉样神经病变
Chafic Karam1, Mamatha Pasnoor2, Richard J Barohn3
1Neuromuscular Division, Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Neurologic clinics
|October 29, 2025
概括
氨基粉症是一种可治疗的多神经病变原因,具有多种类型,如AL和transthyretin氨基粉症. 通过基因测试和生物标志物的早期诊断是有效治疗和改善患者结果的关键.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 病理学 病理学 病理学
背景情况:
- 氨基化症是多神经病的重要原因.
- 它呈现出多种不同的病因,包括粉样蛋白轻链 (AL),粉样蛋白变体 (ATTRv),野生型粉样蛋白 (wrATTR),凝索林和阿波利波蛋白A1 (ApoA-I) 粉样蛋白.
- 最常见的是AL和跨甲基氨基粉症,而AGel和ApoA-I是罕见的,在诊断上具有挑战性.
研究的目的:
- 审查导致多神经病变的amyloidosis的各种病因.
- 突出诊断方面的挑战,并强调及时诊断的重要性.
- 强调患者管理多学科合作的必要性.
主要方法:
- 审查关于粉样性粉症病因和诊断的现有文献.
- 讨论诊断工具,包括基因测试,生物标志物和用刚果红色染色进行组织活检.
- 强调神经病学家和多学科团队的作用.
主要成果:
- 氨基粉症包括几种不同的类型,每个都有独特的特征.
- 尽管取得了进展,但诊断延迟仍然存在,特别是在较罕见的形式.
- 准确的诊断依赖于遗传,生物标志物和组织病理学评估的组合.
结论:
- 早期和准确的粉样性粉症诊断对于有效的治疗至关重要.
- 多学科合作对于优化所有类型的amyloidosis患者护理至关重要.
- 对生物标志物和诊断技术的持续研究是必要的,以克服当前的挑战.
相关概念视频
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Chemical Synapses
11.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.2K

